Patents by Inventor Donald Payan

Donald Payan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Toso as a target for drug screening
    Patent number: 6555314
    Abstract: The present invention is directed to methods for identifying novel compositions which modulate the activity of Toso, and the use of such compositions in diagnosis and treatment of disease.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: April 29, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Donald Payan
  • Small molecule library screening using FACS
    Patent number: 6455263
    Abstract: The present invention relates to methods of screening libraries of small molecules such as combinatorial chemical libraries of organic molecules, including peptides and other chemical libraries, for binding to target molecules, using fluoroscence-activated cell sorting (FACS) machines.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: September 24, 2002
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Donald Payan
  • COMBINATORIAL ENZYMATIC COMPLEXES
    Publication number: 20020064798
    Abstract: The invention relates to the formation of novel in vivo combinatorial enzyme complexes for use in screening candidate drug agents for bioactivity.
    Type: Application
    Filed: June 12, 1997
    Publication date: May 30, 2002
    Inventors: GARRY P. NOLAN, DONALD PAYAN
  • Mammalian protein interaction cloning system
    Patent number: 6316223
    Abstract: The present invention is directed to compositions and methods for a genetic system of detecting protein-protein interactions in a mammalian host cell. Two fusion proteins are made in the host cell. The first fusion protein contains a DNA binding domain which is fused to a so-called bait protein. The second fusion protein consists of a transcriptional activation domain fused to a so-called test protein. The DNA binding domain binds to an operator sequence which controls expression of one or more reporter genes. The transcriptional activation domain is recruited to the promoter through the functional interaction between the bait protein and the test protein. Subsequently the transcriptional activation domain interacts with the basal transcription machinery to activate expression of one or more reporter genes which can be identified and characterized. The individual compositions are useful for analyzing protein-protein interactions between known proteins and to isolate, clone and characterize unknown proteins.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: November 13, 2001
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Donald Payan, Ying Luo, Betty Huang
  • Combinatorial enzymatic complexes
    Publication number: 20010036638
    Abstract: The invention relates to the formation of novel in vivo combinatorial enzyme complexes for use in screening candidate drug agents for bioactivity.
    Type: Application
    Filed: February 20, 2001
    Publication date: November 1, 2001
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Garry P. Nolan, Donald Payan
  • SMALL MOLECULE LIBRARY SCREENING USING FACS
    Publication number: 20010006787
    Abstract: The present invention relates to methods of screening libraries of small molecules such as combinatorial chemical libraries of organic molecules, including peptides and other chemical libraries, for binding to target molecules, using fluoroscence-activated cell sorting (FACS) machines.
    Type: Application
    Filed: March 24, 1998
    Publication date: July 5, 2001
    Inventor: DONALD PAYAN
  • Mammalian protein interaction cloning system
    Patent number: 6114111
    Abstract: The present invention is directed to compositions and methods for a genetic system of detecting protein--protein interactions in a mammalian host cell. Two fusion proteins are made in the host cell. The first fusion protein contains a DNA binding domain which is fused to a so-called bait protein. The second fusion protein consists of a transcriptional activation domain fused to a so-called test protein. The transcriptional activation domain is recruited to the promoter through the functional interaction between the bait protein and the test protein. Subsequently the transcriptional activation domain interacts with the basal transcription machinery to activate expression of one or more reporter genes which can be identified and characterized. The individual compositions are useful for analyzing protein--protein interactions between known proteins and to isolate, clone and characterize unknown proteins. The individual compositions can be used to express the fusion proteins either transiently or stably.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: September 5, 2000
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ying Luo, Betty Huang, Donald Payan
  • Nuclear cyclophilin
    Patent number: 5968802
    Abstract: Cyclophilin-60 proteins, nucleic acids, and monoclonal antibodies are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 1999
    Inventors: Bruce Wang, Donald Payan, Joseph Fisher